Steven Sarkisian, MD
Glaucoma Specialist · Oklahoma City, OKNPI 1386601318
Payments from drug & device makers
Across 1,313 payments — averaging $2748.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2.1M
- AbbVie$1.3M
- Sight Sciences, Inc.$102K
- Ocular Therapeutix, Inc.$51K
- Alcon$42K
- Bausch & Lomb Americas Inc.$25K
- plus $62K from 20 others
Across 6 payments — averaging $10,160 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$59K
- Ocular Therapeutix, Inc.$1K
- Glaukos Corporation$865
- AbbVie$38
What the payments were for
- Consulting fees$234,47657%
- Speaking & faculty fees$115,04128%
- Grants$10,0002%
- Travel & lodging$27,5217%
- Food & beverage$20,7705%
- Gifts$450%
- Other$5,1901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 495 | $2,057,374 |
| AbbVie(2 entities) | 444 | $1,270,504 |
| Sight Sciences, Inc. | 72 | $101,565 |
| Ocular Therapeutix, Inc. | 5 | $50,860 |
| Alcon | 129 | $42,120 |
| Bausch & Lomb Americas Inc. | 49 | $25,023 |
| Beaver-visitec International, Inc. | 8 | $22,015 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 27 | $21,276 |
| Aerie Pharmaceuticals, Inc. | 16 | $13,198 |
| Alcon Research LLC | 2 | $1,733 |
| Iridex Corporation | 9 | $1,071 |
| NEW World Medical,inc. | 7 | $824 |
| Rxsight Inc | 10 | $661 |
| Novartis | 16 | $316 |
| Tearlab Corp | 5 | $125 |
| Harrow Eye, LLC | 4 | $104 |
| Tarsus Pharmaceuticals, Inc. | 4 | $80 |
| Carl Zeiss Meditec USA, Inc. | 2 | $73 |
| Dompe US, Inc. | 2 | $59 |
| Nova Eye, Inc. | 1 | $41 |
| Oyster Point Pharma, Inc. | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
| Omeros Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$64,557
- iStent inject Trabecular Micro-Bypass Stent System$45,734
- XEN$45,448
- iStent Trabecular Micro-Bypass Stent System$37,141
- iDose$26,872
- OMNI$22,591
- VYZULTA$22,388
- iStent inject W$17,151
- Rhopressa$15,972
- Rocklatan$15,856
- iStent$10,000
- AcrySof IQ VIVITY IOL$8,613
- AcrySof IQ PanOptix$8,613
- iDose TR$8,389
- Voyager DSLT$7,000
- Centurion$6,983
- Hydrus Microstent$5,843
- iStent Inject Trabecular Micro-Bypass System$5,693
- XEN GLAUCOMA TREATMENT SYSTEM$5,375
- Travoprost Intraocular Implant - iDose$5,325
How this compares
Too few glaucoma specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 30 | $37,570 |
| LumiganBimatoprost | 43 | $18,367 |
| VyzultaLatanoprostene Bunod | 31 | $16,922 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $13,251 |
| Brinzolamide | 42 | $10,761 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $10,167 |
| RhopressaNetarsudil Mesylate | 21 | $9,570 |
| ProlensaBromfenac Sodium | 23 | $8,216 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $6,103 |
| Timolol Maleate | 183 | $5,779 |
| Travoprost | 20 | $4,555 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $3,617 |
| Prednisolone Acetate | 50 | $3,007 |
| Latanoprost | 183 | $1,986 |
| Acetazolamide ErAcetazolamide | 49 | $1,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,270,504 | $69,188101 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $13,198 | $19,73643 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $25,023 | $16,92231 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $21,276 | $8,21623 claims |
| AlconSimbrinza | $42,120 | $6,10330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Oklahoma City
- Ben HarveyOklahoma City$43K
- Andrew BaileyOklahoma City$3K
- Gregory SkutaOklahoma City$872
- Mahmoud KhaimiEdmond$1.5M
- Basil MathewsEdmond$7K
- Anthony EconomouTulsa$279
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.